anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Nucleic acid polymers (NAPs) are an attractive treatment modality for chronic hepatitis B (CHB), with REP2139 and REP2165 having shown efficacy in CHB patients. A subset of patients achieve functional cure, whereas the others exhibit a moderate response or are non-responders. NAP efficacy has been difficult to recapitulate in animal models, with the duck hepatitis B virus (DHBV) model showing some promise but remaining underexplored for NAP efficacy testing. Here we report on an optimized in vivo DHBV duck model and explore several characteristics of NAP treatment. REP2139 was efficacious in reducing DHBV DNA and DHBsAg levels in approximately half of the treated ducks, whether administered intraperitoneally or subcutaneously. Intrahepatic or serum NAP concentrations did not correlate with efficacy, nor did the appearance of anti-DHBsAg antibodies. Furthermore, NAP efficacy was only observed in experimentally infected ducks, not in endogenously infected ducks (vertical transmission). REP2139 add-on to entecavir treatment induced a deeper and more sustained virological response compared to entecavir monotherapy. Destabilized REP2165 showed a different activity profile with a more homogenous antiviral response followed by a faster rebound. In conclusion, subcutaneous administration of NAPs in the DHBV duck model provides a useful tool for in vivo evaluation of NAPs. It recapitulates many aspects of this class of compound's efficacy in CHB patients, most notably the clear division between responders and non-responders.
PURPOSE: A cosmetic composition containing Zizyphus jujuba Miller leave extract is provided to ensure excellent anti-aging and skin moisturizing effect. CONSTITUTION: A cosmetic composition contains 0.001-30.0 wt% of fermented Zizyphus jujuba Miller leave extract as an active ingredient. The fermentation microorganism is yeast, Lactobacillus, or Bacillus sp. The fermentation is prepared by fermenting at 20-40°C and pH 5-7 for 1-7 days. The fermented Zizyphus jujuba Miller leave extract is compressed concentrate or freeze-dried material. The composition is used for anti-aging and skin moisturizing. The cosmetic composition is manufactured in the form of a lotion, gel, water soluble liquid, cream, essence, oil in water(O/W) type or water in oil(W/O) based basic cosmetic formula, lip gloss, skin cover, foundation, and eye brow pencil.
1. Use of fumagillol or esters thereof formed with saturated or unsaturated (C 1-C12)alkylcarboxylic or (C 1-C12) alkyldicarboxylic acids and of their pharmaceutically acceptable salts for the preparation of medicaments for controlling intestinal infections caused by microsporidia and/or cryptosporidia. 2. Use of fumagillol or esters thereof according to Claim 1 characterized in that said ester represents fumagillin. 3. Use of fumagillol or esters thereof according to Claim 1 characterized in that for controlling intestinal infections the principal parasite of which is Enterocytozoon bieneusi. 4. Use of fumagillol or esters thereof according to Claim 3 characterized in that said ester represents fumagillin. 5. Use of fumagillol or esters thereof according to Claim 1 or 2 characterized in that said medicament is for oral administration. 6. Use of fumagillol or esters thereof according to Claim 3 or 4 characterized in that said medicament represents tablets, gelatin capsules or tablets of prolonged action with controlled liberation. 7. Pharamaceutical composition for controlling intestinal infections caused by microsporidia and/or cryptosporidia for oral administration characterized in that as an active compound it contains saturated or unsaturated (C 1-C12) alkyldicarboxylic acid or one of its pharmaceutically acceptable salts and at least one of its pharmaceutically acceptable excipient and/or carrer. 8. Pharamaceutical composition according to Claim 7 characterized in that said ester represents fumagillin. 9. Pharamaceutical composition according to Claim 7 or 8 characterized in that it contains 1-200 mg of active compound in a single dose. 10. Pharamaceutical composition according to Claim 9 characterized in that it contains 7.5-30 mg of active compound in a single dose.
Polysaccharide nanoparticles that are particularly useful in for example drug and agent delivery, tissue-specific targeting, for medical imaging and diagnosis, as well as modifiers of physico-chemical properties. The nanoparticles can be highly-branched glucose homopolymers and can be characterized by a uniform spherical shape. They are monodisperse, hydrophilic and produce low solution viscosities. The nanoparticles are non-toxic, biocompatible and biodegradable. Also, the process of isolation of said polysaccharide nanoparticles from various organisms including, but not limited to, microorganisms such as bacteria and yeasts. Also provided are methods for chemical conjugation of the polysaccharide nanoparticles with various agents. Also provided are examples of use of the polysaccharide nanoparticles and their derivatives as drug delivery systems and fluorescent diagnostics.
Live-virus vaccine against distemper in carnivores and process for its preparation. The vaccine in question preferably consists of a freeze- dried mixture of a virus and a stabilizer. The virus in the vaccine is one that is registered in the Pasteur Institute under number I-129 and is an attenuated strain of a virus causing distemper in carnivorous animals. This strain is prepared from a wild virus isolated from a mink with distemper by repeated passages in cell cultures of different origins. One of these cultures comes from canine kidneys, another from the kidneys of a human Rh embryo, and a third is a mixed cell culture consisting of cells from canine kidneys and cells from a Japanese quail embryo, this strain having been adapted to the cell culture of the embryo of a Japanese quail embryo and cultured on this medium. In the process for the preparation of the vaccine, an attenuated strain of the distemper virus causing this disease in carnivores is cultured in a cell culture on a nutrient medium, the virus-containing liquid is collected, and the said liquid is then freeze-dried (lyophilized) in the presence of a stabilizer. The process is characterized in that the attenuated virus strain is a virus that is registered in the Pasteur Institute under number I-129 and is one causing distemper in carnivores. It is obtained from a wild-type virus isolated from the blood of a mink with distemper. This procedure involves the following steps: a) a 20-40-fold passage in a cell culture from canine kidneys at a temperature of 37 +/- 1 degrees C, b) a 5-15 fold passage in a cell culture from Rh human embryo kidneys at a temperature of 32 +/- 1 degrees C, c) a 2-7 fold passage in a mixed cell culture consisting of cells from canine kidneys and cells from a Japanese quail embryo at a temperature of 35 +/- 1 degrees C, and finally d) adaptation by a 4-10 fold passage in a cell culture from a Japanese quail embryo. The advantages of the vaccine thus obtained are e.g. that it is not harmful and that it has a high immunogenic and antigenic activity. The vaccine does not contain any alien viruses and can be used for the prophylactic treatment of distemper in carnivores and for eliminating epizootic infections. The vaccine can also be used in aerosol form.
The invention discloses an anti-folate receptor alpha antibody, a conjugate thereof and application thereof, belonging to the technical field of biological medicines. The antibody comprises a heavy chain and a light chain, wherein the heavy chain comprises three CDR regions, and the three CDR regions of the heavy chain respectively have amino acid sequences shown as SEQ ID NO. 1, SEQ ID NO. 2 and SEQ ID NO. 3; the light chain comprises three CDR regions having amino acid sequences shown in SEQ ID NO. 4, SEQ ID NO. 5 and SEQ ID NO. 6, respectively. The antibody has strong affinity with FR alpha; the affinity of the three ADCs to FR α following conjugation of the naked antibody to the therapeutic agent via a linker is similar to that of the naked antibody. The naked antibody and the three ADCs can be used for inhibiting the proliferation of tumor cells with positive FR alpha expression in a targeted mode, and further can be used for preparing medicines for treating or preventing choriocarcinoma, ovarian cancer and lung cancer.
The Ross procedure is an excellent option for aortic valve replacement resulting in outstanding hemodynamic performance and the ability to avoid systemic anticoagulation. The long-term durability of the autograft is generally good but concerns for later aortic root dilation with ensuing neoaortic insufficiency have prompted efforts to stabilize the autograft, root, sinuses and Sino-tubular junction in order to delay or entirely avoid late reinterventions on the neoaortic root. We have employed an inclusion technique, supporting the Auto-graft in a Terumo Gelweave™ Valsalva graft. We performed a retrospective study of all 129 patients undergoing the Ross procedure from 1992 to 2019 at Children's Wisconsin. Fifty-one underwent the supported Ross (SR) and 78 underwent unsupported Ross (UR). Structured clinical data was collected and echocardiograms were reviewed. Median follow-up was 4.9 years (up to 22.6 years) for UR patients and 3.6 years (up to 11.4 years) for SR patients. In order to provide a fair comparison, we sub -analyzed patients aged 10 to 18 years who underwent the Ross procedure, 16 who underwent the UR and 18 patients who underwent the SR. Change in aortic annulus diameter (P = 0.002), aortic sinus diameter (P = 0.001) change in left ventricular function (P = 0.039) and change in aortic insufficiency (P = 0.008) were all worse in UR. The SR is simple, reproducible, and predictable. It seems to prevent change in annulus diameter, sinus diameter and to reduce late neoaortic insufficiency. Longer follow-up with a larger group of patients is required to draw definitive conclusions.
Participants will receive anti-CMV agent best suited to treat the respective participant as per the investigator's prescribed dosing regimen for 8 weeks. Agents of choice include: ganciclovir, valganciclovir, foscarnet, or cidofovir.
The present invention relates to a highly efficient method of preparing modified microcapsules exhibiting selective targeting. These microcapsules are suitable for encapsulation surface attachment of therapeutic and diagnostic agents. In one aspect of the invention, surface charge of the polymeric material is altered by conjugation of an amino acid ester to the providing improved targeting of encapsulated agents to specific tissue cells. Examples include encapsulation of radiodiagnostic agents in 1 μm capsules to provide improved opacification and encapsulation of cytotoxic agents in 100 μm capsules for chemoembolization procedures. The microcapsules are suitable for attachment of a wide range of targeting agents, including antibodies, steroids and drugs, which may be attached to the microcapsule polymer before or after formation of suitably sized microcapsules. The invention also includes microcapsules surface modified with hydroxyl groups. Various agents such as estrone may be attached to the microcapsules and effectively targeted to selected organs.
Laparoscopic distalisation of RYGB type I. The RYGB is modified by dividing the Roux limb (AL) at the jejuno-jejunal anastomosis and re-anastomosed distally to 200 cm from the ileocecal valve using linear staplers, creating a long biliopancreatic limb (BPL). In cases of initial AL lengths shorter than 100 cm, the CC lengths should be adjusted to create a TALL of at least 300 cm.
Mitral valve prolapse (MVP) is the most common valve disease in the western world and recently emerged as a possible substrate for sudden cardiac death (SCD). It is estimated an annual risk of sudden cardiac death of 0.2 to 1.9% mostly caused by complex ventricular arrhythmias (VA). Several mechanisms have been recognized as potentially responsible for arrhythmia onset in MVP, resulting from the combination of morpho-functional abnormality of the mitral valve, structural substrates (regional myocardial hypertrophy, fibrosis, Purkinje fibers activity, inflammation), and mechanical stretch. Echocardiography plays a central role in MVP diagnosis and assessment of severity of regurgitation. Several abnormalities detectable by echocardiography can be prognostic for the occurrence of VA, from morphological alteration including leaflet redundancy and thickness, mitral annular dilatation, and mitral annulus disjunction (MAD), to motion abnormalities detectable with "Pickelhaube" sign. Additionally, speckle-tracking echocardiography may identify MVP patients at higher risk for VA by detection of increased mechanical dispersion. On the other hand, cardiac magnetic resonance (CMR) has the capability to provide a comprehensive risk stratification combining the identification of morphological and motion alteration with the detection of myocardial replacement and interstitial fibrosis, making CMR an ideal method for arrhythmia risk stratification in patients with MVP. Finally, recent studies have suggested a potential role in risk stratification of new techniques such as hybrid PET-MR and late contrast enhancement CT. The purpose of this review is to provide an overview of the mitral valve prolapse syndrome with a focus on the role of imaging in arrhythmic risk stratification. CLINICAL RELEVANCE STATEMENT: Mitral valve prolapse is the most frequent valve condition potentially associated with arrhythmias. Imaging has a central role in the identification of anatomical, functional, mechanical, and structural alterations potentially associated with a higher risk of developing complex ventricular arrhythmia and sudden cardiac death. KEY POINTS: • Mitral valve prolapse is a common valve disease potentially associated with complex ventricular arrhythmia and sudden cardiac death. • The mechanism of arrhythmogenesis in mitral valve prolapse is complex and multifactorial, due to the interplay among multiple conditions including valve morphological alteration, mechanical stretch, myocardial structure remodeling with fibrosis, and inflammation. • Cardiac imaging, especially echocardiography and cardiac magnetic resonance, is crucial in the identification of several features associated with the potential risk of serious cardiac events. In particular, cardiac magnetic resonance has the advantage of being able to detect myocardial fibrosis which is currently the strongest prognosticator.
Physical activity increases the risk of non-contact injuries, mainly affecting muscles, tendons, and ligaments. Genetic factors are recognized as contributing to susceptibility to different types of soft tissue injuries, making this broad condition a complicated multifactorial entity. Understanding genetic predisposition seems to offer the potential for personalized injury prevention and improved recovery strategies. The candidate gene analysis approach used so far, has often yielded inconclusive results. This manuscript reviews the most commonly studied genetic variants in genes involved in the musculoskeletal system's structure and recovery processes (ACTN3, ACE, CKM, MLCK, AMPD1, IGF2, IL6, TNFα, CCL2, COL1A1, COL5A1, MMP3, and TNC). Referring to the literature, it was highlighted that single-gene analyses provide limited insight. On the other hand, novel genetic testing methods identify numerous variants of uncertain physiological relevance. Distinguishing between functionally important variants, modifying variants, and the thousands of irrelevant variants requires advanced bioinformatics methods and basic multiomics research to identify the key biological pathways contributing to injury susceptibility. Tools like the Total Genotype Score (TGS) and Polygenic Risk Score (PRS) offer a more holistic view by assessing the combined effect of multiple variants. However, these methods, while useful in research, lack clinical applicability. In conclusion, it is too early to determine the clinical implications of genetic variability as a tool for improving well-established training and injury prevention methods, as the predictive power of genetic testing for injury predisposition is currently low.
The invention discloses a kind of mankind and mammalian cell expression vector and application thereof, belong to genetically engineered field.This expression vector selects complex body containing beta-globin MAR sequence, beta-interferon MAR sequence, multiple clone site and eucaryon resistant gene on pCAT3-control carrier framework; Does is beta-interferon MAR sequence positioned at SV40 on pCAT3-control carrier framework? promotor upstream, does is beta-globin MAR sequence positioned at SV40 on pCAT3-control carrier framework? late? poly? A? region downstream.Does is the GenBank of described beta-globin MAR sequence numbered: L22754.1, beta-interferon MAR sequence? GenBank is numbered: M83137.1.Carrier of the present invention is applicable to efficiently expressing exogenous gene in the mankind and mammalian cell.
It was recognized that GSM is likely to be underdiagnosed and undertreated9. The North American Menopause Society (NAMS) issued the treatment guideline of GSM in 2014 and encouraged the physicians and nurses to pursue menopausal women to check if they have genitourinary syndrome. GSM is considered a progressive condition in menopausal women, and the primary goal of treatment strategy is symptom relief. Options include lifestyle changes, non-hormonal, and hormonal treatments. Hormonal therapies include both topical and systemic approaches. However, many women reported that substantial concerns about the long-term safety of hormonal products.The patients are aware of the possible relationship between cancer, heart disease, stroke, and estrogen-based treatments10. For considering long-term treatment strategy, estrogen free products of vaginal lubricant or vaginal moisturizer are recommended as first line treatment for those with mild to moderate syndrome.
A medical dictation workflow system can be customized from the selection of available user application programs. A voice interface OCX can interface speech technologies with the selected user application programs of the medical dictation workflow system. The medical dictation workflow system may be directed to generating reports through filling out defined fields. The fields can be generated through a tracking system subscribing to a core reporting system and requesting certain information be captured or through a user. The voice interface OCX can provide macros so a user can customize the fields, navigate among the fields, or fill in the fields with data through a voice recognition engine or a wave player control. The data entered into the fields can be automatically entered into corresponding database elements of a database.
The present disclosure relates to the technical field of microorganisms, and in particular to a Bifidobacterium bifidum (B. bifidum) strain BB—ZO and, use thereof in the preparation. of a product for improving skin quality and reducing pigmentation spots. The B. .bifidum strain. BB—ZO was deposited, in the China General Microbiological Culture Collection Center (CGMCC) on March ll, 2021, with a deposit number of CGMCC 21893. The strain of the present disclosure has prominent permeability for gastric acid barrier, high affinity to intestinal epidermal cells, and excellent colonization effect, and thus is especially suitable for oral administration. Moreover, by activating antioxidant pathway and other pathways, the strain can increase the expression of superoxide dismutase (SOD)—related genes in the body, increase the antioxidant level of the body, and remove pigmentation spots and improve skin quality.
At study enrollment, the patient's scar will be evaluated using the vascularity category of the Vancouver Scar Scale. The vascularity rating is a four item likert scale that rates the scar as normal (0), pink (1), red (2), or purple (3). Scar height will be measured using a diagnostic ultrasound unit with a 20MHz transducer.27 Digital photographs will be taken with a color spectrum scale placed next to the scar. Laser Doppler imaging (LDI) will be used to assess scar perfusion at the regions of interest to determine whether treatment with silicone spay results in measureable changes in scar perfusion as well as to establish the time course over which these changes may be expected to occur. A spray template will then be created for the patient using thermoplastic material. It will consist of three (3) circles with an area of .785 inches, spaced one inch apart, which will section off the test areas. One of the areas will be treated with the spray silicone, one area will be sprayed with spray saline (to serve as a placebo), the remaining area will not be treated and therefore will serve as the control. The order in which each area is treated will be determined using a randomized block, computerized allocation developed by the study statistician. The spray silicone and spray saline will be applied via containers that conceal the contents and the patients will not be allowed to observe the application of the silicone or saline. Although the patient will be blinded to the test areas that have substances applied to them, there will be no blinding in regard to the control area that receives no treatment. The substances will be applied by trained investigators each weekday for a 12-week period to ensure the method of application is consistent. Both substances will be applied at a distance of 1.5 inches from the surface of the skin for a one second period. Patients will be instructed not to wash the treated area for 24 hours and not to apply pressure garments over the area. The treated areas will be re-evaluated and photographed every two weeks for a 12 week period. The clinician conducting the initial scar evaluation and re-evaluations will be blinded to the scar treatment. Each patient will also complete a scar assessment scale.28 The patient's participation in the study will be concluded 12 weeks after the initial treatment and he/she will be given the option of continued use of the spray silicone, resumption/commencement of pressure garment use or the provision of another appropriate scar management program. Because burn scar can take several months to years to reach the scar maturation phase, the patient will still be a candidate for an alternate scar management program if at the conclusion of this study they see no benefit from the use of spray silicone. If at any time during the 12-week period the clinician determines that the scar is worsening, then the patient will be removed from the study and offered another scar management program.
Body mass index of ≥30kg/m2 OR Body mass index of ≥25 kg/m2 with an obesity associated co-morbidity. Will receive receive non-tailored weight management handouts by health coaches.